In vivo models of multiple system atrophy

Movement Disorders

Volumn 20, Issue SUPPL. 12, 2005, Pages

  Fernagut, Pierre Olivier ^a   Ghorayeb, Imad ^b   Diguet, Elsa ^b   Tison, François ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

3 NP; Alpha synuclein; Levodopa unresponsive parkinsonism; MPTP; MSA P; Multiple system atrophy; Pathophysiology

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; LEVODOPA; NEUROTOXIN;

ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; BRAIN INJURY; CORPUS STRIATUM; DISEASE EXACERBATION; DISEASE SEVERITY; DYSTONIA; HINDLIMB; IN VIVO STUDY; INTOXICATION; METHODOLOGY; MONKEY; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SHY DRAGER SYNDROME; STATISTICAL SIGNIFICANCE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TREATMENT PLANNING;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; LEVODOPA; MACACA FASCICULARIS; MICE; MPTP POISONING; MULTIPLE SYSTEM ATROPHY; OXIDOPAMINE; PARKINSONIAN DISORDERS; POINT MUTATION; RATS; SUBSTANTIA NIGRA;

EID: 26444534506     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20541     Document Type: Article

References (43)

1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284-1288.
2. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-1775.
3. Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000;355:495-496.
4. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-393.
5. Tison F, Wenning GK, Daniel SE, Quinn N. The pathophysiology of parkinsonism in multiple system atrophy. Eur J Neurol 1995;2: 435-444.
6. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117(Pt 4):835- 845.
7. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74: 189-192.
8. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990;113(Pt 6):1823-1842.
9. Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neurosci Lett 1997;230:49-52.
10. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998;249:180-182.
11. Kawamoto Y, Akiguchi I, Nakamura S, Budka H. Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Ann Neurol 2002;52:722-731.
12. Hishikawa N, Niwa J, Doyu M, et al. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am J Pathol 2003;163:609-619.
13. Wenning GK, Geser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy: an update. Mov Disord 2003;18(Suppl. 6):S34-S42.
14. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
15. Marshall JF, Ungerstedt U. Striatal efferent fibers play a role in maintaining rotational behavior in the rat. Science 1977;198:62-64.
16. Friehs GM, Parker RG, He LS, Haines SJ, Turner DA, Ebner TJ. Lesioning of the striatum reverses motor asymmetry in the 6-hydroxydopamine rodent model of parkinsonism. J Neural Transplant Plast 1991;2:141-156.
17. Barker R, Dunnett SB. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Exp Brain Res 1994;101:365-374.
18. Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 1996;11:522-532.
19. Scherfler C, Puschban Z, Ghorayeb I, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000;99: 43-54.
20. Ghorayeb I, Puschban Z, Fernagut PO, et al. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 2001;167: 133-147.
21. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. "Minimal change" multiple system atrophy. Mov Disord 1994;9: 161-166.
22. Waldner R, Puschban Z, Scherfler C, et al. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience 2001;102:581-592.
23. Ghorayeb I, Fernagut PO, Hervier L, Labattu B, Bioulac B, Tison F. A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 2002;115:533-546.
24. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine, agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15(Pt 2):3863-3875.
25. Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnett SB. The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991;36:219-228.
26. Maragos WF, Jakel RJ, Pang Z, Geddes JW. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp Neurol 1998;154:637-644.
27. Buisson A, Pateau V, Plotkine M, Boulu RG. Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid. Neurosci Lett 1991;131:257-259.
28. Jakel RJ, Maragos WF. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 2000;23:239-245.
29. Ghorayeb I, Fernagut PO, Aubert I, et al. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Mov Disord 2000;15:531-536.
30. Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335:34-38.
31. Stefanova N, Puschban Z, Fernagut PO, et al. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol (Berl) 2003;106:157-166.
32. Fernagut PO, Diguet E, Bioulac B, Tison F. MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 2004;185:47-62.
33. Fernagut PO, Diguet E, Jaber M, Bioulac B, Tison F. Dopamine transporter knock-out mice are hypersensitive to 3-nitropropionic acid-induced striatal damage. Eur J Neurosci 2002;15:2053-2056.
34. Reynolds DS, Carter RJ, Morton AJ. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 1998;18:10116-10127.
35. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
36. Chou H, Ogawa N, Asanuma M, Hirata H, Mori A. Dopamine deficiency in the weaver mutant mouse: an animal model of olivopontocerebellar atrophy. Res Commun Chem Pathol Pharmacol 1991;74:117-120.
37. Patil N, Cox DR, Bhat D, Faham M, Myers RM, Peterson AS. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nat Genet 1995;11:126-129.
38. Bandmann O, Sweeney MG, Daniel SE, et al. Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. Neurology 1997;49:1598-1604.
39. Zuscik MJ, Sands S, Ross SA, et al. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med 2000;6:1388-1394.
40. Zuscik MJ, Chalothorn D, Hellard D, et al. Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor. J Biol Chem 2001;276: 13738-13743.
41. Papay R, Zuscik MJ, Ross SA, et al. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J Neurochem 2002;83:623-634.
42. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, Wenning GK. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005;166:869-876.
43. Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847-859.